Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need.
Daiichi Sankyo
Zielstattstr. 48 81379 Munich Germany
URL: https://www.daiichi-sankyo.eu/
MSD
At MSD, known as Merck & Co., Inc., Rahway, NJ, in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.
For more information, visit www.msd.de and connect with us on LinkedIn, Instagram und YouTube.
MSD Sharp & Dohme GmbH
Address: Levelingstraße 4a, 81673 Müchen
E-Mail: [email protected]
Telefon: +49 89 / 20 300 4500
Pierre Fabre
Founded in 1962 in the south-west of France, the company manufactures 90% of its products in France and employs around 10,000 people worldwide. 86% of the company is owned by the Pierre Fabre Foundation, a government-approved non-profit foundation, and by its own employees under an international employee participation program.
Pierre Fabre Laboratories ist ein führendes französisches Unternehmen im Bereich Medizin und Schönheitspflege mit vier Jahrzehnten Erfahrung in der Innovation, Entwicklung, Herstellung und Vermarktung von Onkologika. Das Unternehmen widmete 2022 rund 80 % seiner F&E-Ausgaben der Onkologie, wobei der Schwerpunkt auf gezielten Therapien lag.
Das 1962 im Südwesten Frankreichs gegründete Unternehmen stellt 90 % seiner Produkte in Frankreich her und beschäftigt weltweit rund 10 000 Mitarbeiter. Das Unternehmen befindet sich zu 86 % im Besitz der Pierre-Fabre-Stiftung, einer staatlich anerkannten gemeinnützigen Stiftung, und der eigenen Mitarbeiter im Rahmen eines internationalen Mitarbeiterbeteiligungsprogramms.
Pierre Fabre Pharma GmbH
Neuer Messplatz 5, 79108 Freiburg
Tel: +49 (0)761 45261-0
Email: [email protected]
URL: www. pierre-fabre.com
Therakos
Therakos UK Ltd specialises in photopheresis technology and has been providing ECP (Extracorporeal Photopheresis) treatment for over 35 years.
The THERAKOSTM CELLEX™ Photopheresis System is the world’s only fully integrated and validated ECP system and is used by over 300 treatment centres in over 30 countries worldwide.
Beyond the THERAKOS™ CELLEX™ Photopheresis System, Therakos Healthcare Limited offers a comprehensive range of support services to help enable healthcare professionals (HCPs) to deliver ECP immunomodulation to patients.
Please see www.therakos.eu/isi for approved Indications and Important Safety Information.
To learn more about this product visit www.therakos.eu.
Therakos (UK) Ltd, 3 Lotus Park, The Causeway, Staines-Upon-Thames, Surrey, TW18 3AG, UK
Telephone +44 (0) 1784 636 700
Email address: [email protected]
Website: globalcorporate.therakos.com / Therakos.eu
Alexion
As a leader in rare diseases for more than 30 years, Alexion, AstraZeneca Rare Disease, is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, and cardiology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 70 countries. Alexion Pharma Germany GmbH is located in Munich, Germany. For more information, please visit: www.alexion.de.
Alexion Pharma Germany GmbH
Landsberger Straße 300
D-80687 München
Tel: +49 (0) 89 45 70 91 300
Fax: +49 (0) 89 51 51 87 21
Email: [email protected]
Astellas
Astellas is a pharmaceutical company committed to turning innovative science into value for patients. Changing tomorrow is the ethos thaat guides everything we do.
Working at the forefront of healthcare change, Astellas invests in new medicines, technologies and therapeutic areas, and builds partnerships and networks with others who share our vision to improve the future of medicine.
Digital Banner
Astellas Pharma GmbH
Ridlerstr. 57, 80339
München/Munich-Germany
URL: https://www.astellas.com/eu
GSK
GSK is a global biopharma company. Our purpose is to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade for health impact, shareholder returns and thriving people. We prevent and treat disease with specialty medicines, vaccines and general medicines. At the heart of this is our R&D focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas: Respiratory, Immunology & Inflammation; Oncology; HIV and Infectious Diseases – _to impact health at scale. We operate responsibly for all our stakeholders.
https://de.gsk.com
http://www.gsk.com
YouTube: GSK Deutschland – YouTube
GlaxoSmithKline GmbH & Co. KG
Prinzregentenplatz 981675
München
Germany
+ 49 (0) 89 360 44 0
Medical Information & Service Center:
+ 49 (0) 800 1 22 33 55 (8 am to 6 pm)
[email protected]
Incyte
Since 2002 Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders.
Incyte’s unique expertise in medicinal chemistry and biology have enabled us to create a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing portfolio of medicines across Oncology and Inflammation & Autoimmunity.
Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For more information, visit Incyte.com and follow @Incyte
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) ist ein globales biopharmazeutisches Unternehmen, dessen Ziel es ist, durch Innovationen das Leben von Patienten und ihren Familien zu verändern.
Wir haben uns der Entwicklung von potenziell lebensverändernden Medikamenten für Menschen mit schweren Krankheiten verschrieben, für die es oft nur begrenzte oder gar keine therapeutischen Optionen gibt.
Jazz verfügt über ein vielfältiges Portfolio an Medikamenten, darunter ein führendes Epilepsiemedikament, und ein wachsendes Portfolio an Krebstherapien.
Unser patientenorientierter und wissenschaftsgeleiteter Ansatz ermöglicht uns bahnbrechende Fortschritte bei der Erforschung und Entwicklung der innovativen Therapeutika in unserer umfangreichen Pipeline in den Bereichen Onkologie und Neurowissenschaften.
Jazz hat seinen Hauptsitz in Dublin, Irland. Mit unseren Forschungs- und Entwicklungslaboren, Produktionsstätten und Mitarbeitern in zahlreichen Ländern setzen wir uns weltweit für Patienten ein.
Vist www.defitelio.de
DE-JPC-2400002
Erstellungsdatum: November 2024
PROVIREX
PROVIREX Genome Editing Therapies GmbH is a pioneering biotech company dedicated to developing groundbreaking genome editing therapies for the cure of HIV. Unlike conventional gene editing methods, our recombinase-based approach achieves exceptional accuracy and safety by directly excising viral genomes without relying on cellular DNA repair mechanisms.
At our unique therapy hub in Hamburg, we operate Europe’s only S3** biosafety cleanrooms specifically designed for advanced therapy medicinal product (ATMP, e.g. CAR-T cells) manufacturing. We are interested in partnering for the production of ATMPs in our S3** GMP-compliant clean room production facilities in Hamburg which are registered under GenTSV in Germany.
Dr. Jan Claas-von Jachmann
CEO & Partner
PROVIREX Genome Editing Therapies GmbH
Elly-See-Strasse 1 22547
Hamburg – Germany
[email protected]
www.provirex.de
